Dr. Qian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 E Jefferson St
Ste A1
Seattle, WA 98122Phone+1 206-320-2200Fax+1 206-320-2560
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2007 - 2010
SSM St Mary's Hospital-St LouisInternship, Internal Medicine, 2006 - 2007
Shanghai Jiao Tong University School of MedicineClass of 1993
Certifications & Licensure
WA State Medical License 2012 - 2025
MO State Medical License Active through 2013- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Vitamin D Supplementation in Multiple Sclerosis Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.Enrique Alvarez, Lawrence Steinman, Edward J Fox, Hans-Peter Hartung, Peiqing Qian
Frontiers in Neurology. 2024-01-01 - 17 citationsHigh-dose vitamin Dsupplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial.Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo
Eclinicalmedicine. 2023-05-01 - 59 citationsUblituximab versus Teriflunomide in Relapsing Multiple Sclerosis.Lawrence Steinman, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian
The New England Journal of Medicine. 2022-08-25
Press Mentions
ACTRIMS 2023: Most on Briumvi Show No MS Activity After 6 MonthsMarch 2nd, 2023- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (Ublituximab) in Multiple Sclerosis to Be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumFebruary 14th, 2023
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
